No survival benefit of CPX-351 over FLAG-Ida in AML patients with adverse cytogenetics Presented ByProf. Nigel Russell, Guy's and St Thomas' NHS Foundation Trust, UK TrialPhase 3, AML19 ConferenceEHA 2022 1 July, 2022 11:49
Comparable effectiveness of CPX-351 and venetoclax plus HMA in older AML patients Presented ByDr Justin Grenet, Weill Cornell Medical Center, NY, USA ConferenceASH 2021 4 February, 2022 11:51